9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium

By Kindler Hedy   Avadhani Anjali   Wade-Oliver Kurombi   Karrison Theodore   Mani Sridhar   Vokes Everett  

Investigational New Drugs, Vol. 22, Iss. 3, 2004-08 ,pp. : 323-327

Springer Publishing Company

Access to resources Recommend Favorite

Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer

By Denduluri Neelima   Lee James   Walshe Janice   Berman Arlene   Vatas Ujala   Chow Catherine   Steinberg Seth   Cox Michael   Low Jennifer   Swain Sandra  

Investigational New Drugs, Vol. 25, Iss. 1, 2007-02 ,pp. : 63-67

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia

By Gomez-Abuin Gonzalo   Winquist Eric   Stadler Walter   Pond Greg   Degendorfer Pamela   Wright John   Moore Malcolm  

Investigational New Drugs, Vol. 25, Iss. 2, 2007-04 ,pp. : 181-185

Springer Publishing Company

Access to resources Recommend Favorite

Phase II trial of dolastatin-10 in patients with advanced breast cancer

By Perez Edith   Hillman David   Fishkin Paul   Krook James   Tan Winston   Kuriakose Phillip   Alberts Steven   Dakhil Shaker  

Investigational New Drugs, Vol. 23, Iss. 3, 2005-06 ,pp. : 257-261

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial

By Li Tianhong  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 741-748

Springer Publishing Company

Access to resources Recommend Favorite